All News
ACR24: Rheumatology Roundup
Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.
Read Article
Maximizing DMARDs to Strive for Steroid-Free Remission in RA
In 1950, three scientists were awarded the Nobel Prize for their groundbreaking discovery of steroids, heralded at the time as a "miracle cure" for rheumatoid arthritis (RA).
Read Article
Novel and Emerging Therapies in Psoriatic Arthritis
Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA.
Read Article
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/ASErsKTNQ6 https://t.co/d1BRW92vju
Dr. John Cush RheumNow ( View Tweet)
In a phase II DBRPCT, Cenerimod (sphingosine-1-phosphate recptr modulator) was not shown effective (vs PBO) at 12 mos in active, SLE pts. CARE study enrolled 427 SLE pts who were randomized to Placebo or 3 different doses of CEN - primary endpoint was not met.… https://t.co/AR6NsEsv8S https://t.co/i89ANl5dai
Dr. John Cush RheumNow ( View Tweet)
Ozempic will change rheumatology @drdavidliew
Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/lELDs7Yy5W https://t.co/wuXZR4vkx8
Dr. John Cush RheumNow ( View Tweet)
Worried about CV Risk and JAKi? What about the Steroids?
Dr. David Liew discusses abstracts 1981 and 2673, presented at #ACR24
https://t.co/OkMgIqxl2A https://t.co/1DVapGcWUn
Dr. John Cush RheumNow ( View Tweet)
Is Frequent Lab Monitoring Necessary?
Dr. Bella Mehta discusses abstract 2619, Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients, presented at #ACR24.
https://t.co/vwPueeAVhO https://t.co/5wyTahjMAu
Dr. John Cush RheumNow ( View Tweet)
Maximizing DMARDs to Strive for Steroid-Free Remission in RA
In 1950, three scientists won the Nobel Prize for discovering steroids, initially hailed as a "miracle cure" for RA. However, within a year, unrelated side effects like pain and fatigue emerged. Despite these issues,… https://t.co/dQEjXzxU0U https://t.co/NqyZHfBiId
Dr. John Cush RheumNow ( View Tweet)
Cumulative Steroid Use and Cardiovascular Events
Dr. Mrinalini Dey abstract 1719, Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis: A Nested Case-Control Study, presented at #ACR24.… https://t.co/DqkDgOwsP9 https://t.co/RXRU05UPoh
Dr. John Cush RheumNow ( View Tweet)
Methotrexate to Prevent RA, Clear as Mud
Intervention in individuals predisposed to rheumatoid arthritis (RA), aiming for prevention, is a significant topic. Seropositivity for rheumatoid factor and ACPA can precede RA by years. Some patients experience a pre-RA arthralgia… https://t.co/D51CoZAzce https://t.co/lgZalnDeb3
Dr. John Cush RheumNow ( View Tweet)
Changing Mindsets about Methotrexate Side Effects
Dr. Mrinalini Dey discusses abstract 1676, presented at #ACR24.
https://t.co/8RXBWUioee https://t.co/liQ1hN4Xtr
Dr. John Cush RheumNow ( View Tweet)
Where there’s smoke, there’s flare: how pollution fuels RA
The WHO has declared climate change to be the greatest threat to human health in the 21st century, likely to contribute to an additional 250,000 deaths annually between 2030 and 2050 #ACR24
https://t.co/efVzSHXN91 https://t.co/AxRyGpqQFa
Dr. John Cush RheumNow ( View Tweet)
Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety… https://t.co/9z9lorLtp0 https://t.co/XZRvm0S585
Dr. John Cush RheumNow ( View Tweet)
Playing it Safe with RA? JAK vs. TNF Debate
The ORAL surveillance trial raised safety concerns that the janus kinase inhibitor (JAKi) tofacitinib was associated with an increased incidence of cancer and major adverse cardiovascular events (MACE), compared to tumor necrosis… https://t.co/sUSdRKRxEF https://t.co/XcjOqGlLVX
Dr. John Cush RheumNow ( View Tweet)
SELECT-GCA: Efficacy and Safety of Upadacitinib
Dr. Richard Conway discusses abstract 0770, presented at #ACR24
https://t.co/C9HZIMP9JK https://t.co/zVhFAfLBQe
Dr. John Cush RheumNow ( View Tweet)
NEW ONLINE POSTER: Safety of a JAKi presented at EULAR 2024!
View safety across 15,000 patient-years of data from 11 Phase 3 trials, including adult patients with RA, PsA, AS, and nr-axSpA. This poster is sponsored by AbbVie US Medical Affairs.
https://t.co/gIFWRqOGmD https://t.co/L0YttKihdf
Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors in GCA?
We have a phase 3 trial in giant cell arteritis back on the opening day plenary stage. The SELECT-GCA study, looking at upadacitinib in GCA, was scheduled to anchor the #ACR24 opening plenary for a reason - it is highly notable and badly needed.… https://t.co/aJ3uao1wD7 https://t.co/6ao2OoODHg
Dr. John Cush RheumNow ( View Tweet)
ANCA Vasculitis "Eye": Can rituximab help?
Dr. Janet Pope discusses abstract 0726 at #ACR24
https://t.co/KzYcmjon8D https://t.co/KDIi1vJE4P
Dr. John Cush RheumNow ( View Tweet)
ORAL Surveillance - Is Statin Use the Problem/Solution?
The findings from ORAL Surveillance Study have been a dominant conversation at #ACR24, with the seminal findings and subsequent analyses a target of debate.
https://t.co/Nn9KSL4dlv https://t.co/gHPwK35eEd
Dr. John Cush RheumNow ( View Tweet)
